Also, all the NK cell phenotypes were differentially abundant across cancers (NK CD16+ Padj = 0.0048; NK CD16- Padj = 0.021, and NK Padj = 0.048, Benjamini-Hochberg corrected Kruskal-Wallis test), and were upregulated in different phases of CML in comparison to other cancers (NK CD16+ log2FC = 2.157, Padj = 0.00002; NK CD16- log2FC = 0.754, Padj = 0.018; and NK log2FC = 0.778, Padj = 0.0178, Benjamini-Hochberg corrected Mann-Whitney test, Fig. 1f, Supplementary Fig. 4a). This evidence concerns the gene FCGR3A and chronic myelogenous leukemia, BCR-ABL1 positive.